장기칩(Organs-on-chips) 시장 : 소재, 제품, 기술, 장기 유형, 용도, 최종 사용자별 예측(2026-2032년)

The Organs-on-chips Market was valued at USD 212.96 million in 2025 and is projected to grow to USD 278.79 million in 2026, with a CAGR of 35.24%, reaching USD 1,762.49 million by 2032.

A concise overview of organs-on-chips evolution, stakeholder priorities, and the strategic imperative for integrating microphysiological systems into translational pipelines

The organs-on-chips field has matured from academic curiosity to a pivotal technology enabling closer replication of human physiology outside the body, and this introduction situates the technology within the strategic agendas of research institutions and industry leaders. Early work focused on demonstrating feasibility; today emphasis has shifted toward reproducibility, integration with standardized laboratory workflows, and compatibility with downstream discovery and translational pipelines. As a result, developers and adopters increasingly evaluate platforms not only for biological fidelity but also for materials, manufacturability, and data interoperability.

Across laboratories and commercial teams, material choices such as Glass, PDMS, and Thermoplastics drive device performance, manufacturability, and regulatory acceptability, shaping design decisions from prototyping through scaled production. Concurrently, the product landscape spans Consumables, Instruments, and Software; consumables encompass essential items including Microplates and Reagents that determine day-to-day experiment throughput and cost structure. Technology modalities vary from Microfluidic Chips, which include both Multi Layer Chips and Single Layer Chips, to Multi Organ Chips and Single Organ Chips, enabling applications that range from focused organ studies to interconnected system-level investigations.

End users span Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, the latter of which includes both Global Pharma and Specialty Pharma entities with differing risk tolerances and adoption timelines. Common applications include Disease Modeling, Drug Discovery with High Throughput Screening and Lead Optimization activities, Personalized Medicine, and Toxicity Testing. Organ types addressed in current development efforts include Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based strategies, and Lung, each presenting distinct biological, analytical, and regulatory challenges. This introduction frames the remainder of the executive summary by highlighting the converging priorities of biological relevance, industrial scalability, and integration into established R&D workflows.

How rapid technological maturation, modular integration, and changing end-user expectations are reshaping adoption pathways and commercial strategies in organ-on-chip innovation

The organs-on-chips landscape is undergoing transformative shifts characterized by technological maturation, consolidation of workflows, and evolving expectations from funders and regulators, and these changes are reshaping adoption pathways. New fabrication approaches and materials science innovations have reduced the gap between prototyping and manufacturable devices; the choice between Glass, PDMS, and Thermoplastics now reflects a deliberate trade-off among biological compatibility, optical clarity, and production scalability. As a result, organizations are re-evaluating platform roadmaps to prioritize compatibility with automated handling and imaging systems.

In product strategy, the industry is moving beyond siloed instruments toward integrated solutions that pair consumables such as Microplates and Reagents with interoperable Instruments and Software, enabling end users to deploy workflows with less in-house engineering overhead. The microfluidic technology base itself is diversifying; Multi Layer Chips and Single Layer Chips offer different fluidic control and fabrication cost profiles, while Multi Organ Chips create opportunities for system-level pharmacology and single organ chips retain roles in focused mechanistic studies. This technological diversification is accompanied by deeper engagement from Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, the latter with distinct priorities between Global Pharma and Specialty Pharma players.

Applications are broadening in parallel: Disease Modeling and Toxicity Testing remain core, while Drug Discovery workflows increasingly incorporate High Throughput Screening and Lead Optimization stages tailored to organ-specific readouts. Personalized Medicine initiatives are leveraging patient-derived cells in organ-specific contexts like Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based liver systems, and Lung, driving renewed attention to donor variability, cell sourcing, and standardized protocols. These shifts collectively emphasize interoperability, standardization, and data robustness as the criteria that will separate widely adopted platforms from niche academic prototypes.

An assessment of the cumulative operational and strategic effects of newly implemented tariff policies on supply chains, sourcing decisions, and R&D timelines in 2025

The introduction of elevated tariff measures in 2025 has compelled industry participants to reassess supply chain strategies, procurement timing, and geographic sourcing decisions for components and finished systems, and these effects are cumulative across the value chain. Many device makers rely on specialized components, including precision glass, polymer substrates such as PDMS and thermoplastic resins, microfabrication tooling, and outsourced instrumentation modules. When tariffs affect imports of raw materials or subassemblies, manufacturers confront higher landed costs that influence decisions about pricing, vendor selection, and inventory management. Consequently, teams are deploying hedging strategies, including multi-sourcing, increased local stocking, and in some cases, partial relocation of assembly activities closer to key customer bases.

For consumables-Microplates and Reagents in particular-the tariff environment has amplified incentives to localize reagent production or to qualify multiple suppliers across jurisdictions to avoid single points of failure. Software and digital deliverables are less directly impacted by tariffs but encounter knock-on effects through delays in hardware shipments and integration testing, which in turn affect project timelines for instrument-based deployments. In addition, Contract Research Organizations and biotechnology firms that depend on imported instrumentation have had to revisit project budgets and timelines to incorporate procurement lead times, customs clearance variability, and potential retesting to ensure regulatory compliance when components are re-sourced.

These operational adjustments are also influencing strategic partnerships. Companies are increasingly open to co-manufacturing agreements, strategic sourcing alliances, and regional distribution partnerships to mitigate tariff exposure. Regulatory considerations intersect with trade policy; for example, qualification of alternative materials or substitutes may trigger additional validation requirements, particularly for liver models that depend on Hepatocyte Based or Spheroid Based systems where biological performance must be demonstrated. In sum, the cumulative impact of tariff changes has led to more resilient, albeit more complex, supply chain designs and has accelerated conversations about nearshoring, supplier diversification, and long-term contractual arrangements with manufacturers and distributors.

Detailed segmentation analysis revealing how material, product, technology, end-user, application, and organ-specific choices influence adoption, validation, and commercial strategy

Segment-specific dynamics shape how developers and purchasers prioritize platforms, and understanding these nuances is essential for effective portfolio management. Material choices among Glass, PDMS, and Thermoplastics influence not only device performance but also optical compatibility for high-content imaging and the feasibility of scaling production. Glass offers excellent optical properties and chemical resistance but can raise fabrication complexity; PDMS remains attractive for rapid prototyping and gas permeability, whereas Thermoplastics provide industrial manufacturability and lower per-unit costs when volumes justify tooling investments.

Product segmentation into Consumables, Instruments, and Software highlights differing margins, service models, and customer interactions. Consumables, which include Microplates and Reagents, generate recurring revenue and require robust supply chain continuity; Instruments demand higher upfront investment and are often paired with long-term service contracts; Software enables data standardization, analytics, and integration with laboratory information management systems, influencing stickiness and cross-sell potential. Within technology choices, Microfluidic Chips present both Multi Layer Chips and Single Layer Chips variants that trade off control complexity against ease of manufacture, while Multi Organ Chips enable emergent phenotypes relevant to systemic pharmacology and Single Organ Chips support targeted mechanistic studies.

End users exhibit distinct adoption behaviors: Academic Institutes prioritize flexibility and cost-effectiveness for hypothesis-driven research; Biotechnology Companies emphasize speed to proof-of-concept and potential for platform licensing; Contract Research Organizations focus on throughput, repeatability, and compliance; Pharmaceutical Companies, whether Global Pharma or Specialty Pharma, evaluate platforms through the lens of portfolio alignment, regulatory risk reduction, and potential to accelerate candidate selection. Applications drive technical and operational requirements: Disease Modeling and Toxicity Testing demand physiological fidelity and validated readouts, Drug Discovery workflows such as High Throughput Screening and Lead Optimization require scalability and automation, and Personalized Medicine depends on compatibility with patient-derived cells. Organ-specific considerations-Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based strategies, and Lung-further determine cell sourcing, assay development, and validation pathways. Integrating these segmentation lenses enables more precise prioritization of R&D investment and commercial go-to-market tactics.

How geographic differences in manufacturing strength, regulatory environments, and research ecosystems shape commercialization and supply chain strategies globally

Regional dynamics fundamentally influence supply chain resilience, regulatory approaches, and partnership strategies, and understanding geographic variation is critical for deployment and commercialization plans. In the Americas, strong demand from established pharmaceutical and biotechnology hubs is driving early commercial uptake, supporting investments in localized assembly and partnerships with contract manufacturers to reduce exposure to cross-border tariffs and shipping disruptions. Academic research centers and startups in the region continue to contribute to innovation pipelines, and regional policy initiatives around life sciences investment are encouraging translational collaborations that connect device developers with clinical and preclinical testing sites.

In Europe, Middle East & Africa, regulatory harmonization efforts and a robust ecosystem of contract research organizations create an environment favorable to standardized validation and collaborative development projects. European research consortia and specialty pharma players often emphasize reproducibility and compliance with stringent safety frameworks, which inform material selection and device qualification strategies. Across the Middle East and Africa, nascent adoption is driven by targeted academic-industry partnerships and investments in translational capacity-building.

Asia-Pacific presents a diverse landscape, with strong manufacturing capabilities, extensive supply chains for thermoplastic components, and significant growth in biotechnology entrepreneurship. The region's manufacturing depth supports rapid scaling of consumables and instruments, while major research universities and CROs foster use cases in Drug Discovery, Disease Modeling, and toxicity assessment. These geographic differences mean that companies must tailor commercialization and partnership models to regional strengths, balancing proximity to end users with access to specialized suppliers and regulatory pathways.

Competitive and partnership dynamics driven by vertical integration of consumables, instrumentation, and software, and the strategic value of validated workflows and manufacturable materials

Competitive dynamics in the organs-on-chips domain are evolving as companies refine capabilities across device engineering, biologics integration, and software analytics, and strategic differentiation increasingly rests on ecosystem orchestration rather than single-technology advantage. Leading firms and innovative startups alike are focusing on vertically integrated offerings that combine high-quality consumables such as Microplates and Reagents with robust Instruments and data-centric Software, which together lower the technical entry barrier for end users and create recurring revenue opportunities.

Organizations that can demonstrate validated workflows for critical applications such as Disease Modeling and Toxicity Testing, and who can align device materials with manufacturability considerations spanning Glass, PDMS, and Thermoplastics, are better positioned to secure strategic partnerships with Contract Research Organizations and pharmaceutical partners. Similarly, technology leaders who offer flexible microfluidic architectures-balancing Multi Layer Chips and Single Layer Chips capabilities along with Multi Organ and Single Organ configurations-create value by addressing both high-throughput discovery requirements and detailed mechanistic studies. Strategic moves such as licensing biological models, forming reagent supply alliances, and investing in software platforms that enable standardized data capture and analytics are shaping the competitive landscape.

Buy-side behavior also favors providers that can support varied end users, from Academic Institutes seeking cost-effective, adaptable systems to Global Pharma requiring rigorous validation and Specialty Pharma interested in niche applications. Companies that invest in regulatory expertise, scalable manufacturing, and service infrastructures to support long-term programs will likely see higher customer retention and broader adoption across application domains.

Practical strategic and operational steps for executives to accelerate adoption, reduce validation risk, and build resilient, scalable organ-on-chip business models

Industry leaders should pursue a set of pragmatic, actionable measures that align technological capability with commercial and operational resilience, and these moves will accelerate adoption while managing execution risk. First, prioritize material strategies that balance biological performance and manufacturability by qualifying Glass, PDMS, and Thermoplastic options early in development cycles to reduce late-stage surprises and validation burdens. Second, design product roadmaps that integrate Consumables like Microplates and Reagents with Instruments and Software to create seamless workflows; bundling consumables with instruments can improve lifecycle economics and strengthen customer relationships.

Third, diversify supply chains and establish regional manufacturing or assembly options to mitigate tariff-related and logistical risks, while negotiating multi-year agreements with key suppliers to secure continuity for critical consumables. Fourth, in technology development, maintain modularity that supports both Multi Layer Chips and Single Layer Chips variants and offers pathways to Multi Organ Chips integration, so customers can scale from single-organ studies to system-level investigations without wholesale platform replacement. Fifth, prioritize end-user engagement by developing tailored offerings for Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, with distinct service and validation packages for Global Pharma and Specialty Pharma customers.

Finally, invest in data standards and software platforms that enable reproducibility, cross-lab comparability, and integration with laboratory information systems to support Drug Discovery activities such as High Throughput Screening and Lead Optimization, as well as Disease Modeling and Personalized Medicine applications. Taken together, these steps will reduce adoption friction and create defensible commercial positions.

A rigorous mixed-methods research approach combining stakeholder interviews, technical assessments, and regional supply chain analysis to inform practical deployment and partnership decisions

This research employed a mixed-methods approach that combined qualitative industry interviews, technical literature review, and comparative analysis of device architectures and supply chain pathways, ensuring a balanced view of scientific, commercial, and operational factors. Primary insights were gathered through structured interviews with stakeholders spanning Academic Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, which provided perspectives on validation criteria, procurement practices, and integration challenges with existing R&D workflows.

Technical assessment examined differences in material properties among Glass, PDMS, and Thermoplastics and evaluated how fabrication choices such as Multi Layer Chips versus Single Layer Chips influence manufacturability and functional readouts. The methodology also included laboratory workflow mapping to understand how Consumables including Microplates and Reagents interface with Instruments and Software across applications like Disease Modeling, Drug Discovery with High Throughput Screening and Lead Optimization, Personalized Medicine, and Toxicity Testing. Regional analysis considered manufacturing capabilities, regulatory frameworks, and ecosystem maturity across the Americas, Europe, Middle East & Africa, and Asia-Pacific to highlight pragmatic deployment considerations.

Where possible, findings were triangulated against publicly available technical reports, patent landscapes, and case studies of platform validation to ensure reliability. Throughout the process, emphasis was placed on identifying operational constraints and adoption barriers rather than projecting quantitative market trajectories, enabling recommendations that are directly actionable for R&D, commercial, and supply chain leaders.

Key takeaways on how technical rigor, materials strategy, and supply chain resilience determine the pace and breadth of organs-on-chips adoption in research and industry

In conclusion, organs-on-chips are transitioning from experimental platforms to practical tools that can materially influence drug discovery, toxicity assessment, and personalized medicine pathways, provided developers and buyers align on reproducibility, materials strategy, and integration capabilities. The interplay between material selection, device architecture, and consumable ecosystems shapes not only experimental outcomes but also the feasibility of scaling and commercializing solutions across diverse end users. Addressing supply chain resilience and regulatory qualification early in development reduces downstream risk and enables more reliable adoption by Contract Research Organizations and pharmaceutical partners.

Looking forward, companies that deliver validated, interoperable solutions and invest in software and data standardization will capture opportunities across Disease Modeling, High Throughput Screening and Lead Optimization activities, and organ-specific use cases in Gut, Heart, Kidney, Liver with Hepatocyte Based and Spheroid Based systems, and Lung. By integrating technical rigor with pragmatic commercialization and sourcing strategies, stakeholders can accelerate impact while managing operational complexity.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Organs-on-chips Market, by Material

• 8.1. Glass
• 8.2. PDMS
• 8.3. Thermoplastics

9. Organs-on-chips Market, by Product

• 9.1. Consumables
  • 9.1.1. Microplates
  • 9.1.2. Reagents
• 9.2. Instruments
• 9.3. Software

10. Organs-on-chips Market, by Technology

• 10.1. Microfluidic Chips
  • 10.1.1. Multi Layer Chips
  • 10.1.2. Single Layer Chips
• 10.2. Multi Organ Chips
• 10.3. Single Organ Chips

11. Organs-on-chips Market, by Organ Type

• 11.1. Gut
• 11.2. Heart
• 11.3. Kidney
• 11.4. Liver
  • 11.4.1. Hepatocyte Based
  • 11.4.2. Spheroid Based
• 11.5. Lung

12. Organs-on-chips Market, by Application

• 12.1. Disease Modeling
• 12.2. Drug Discovery
  • 12.2.1. High Throughput Screening
  • 12.2.2. Lead Optimization
• 12.3. Personalized Medicine
• 12.4. Toxicity Testing

13. Organs-on-chips Market, by End User

• 13.1. Academic Institutes
• 13.2. Biotechnology Companies
• 13.3. Contract Research Organizations
• 13.4. Pharmaceutical Companies
  • 13.4.1. Global Pharma
  • 13.4.2. Specialty Pharma

14. Organs-on-chips Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Organs-on-chips Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Organs-on-chips Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. United States Organs-on-chips Market

18. China Organs-on-chips Market

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025
• 19.5. AIM Biotech Pte. Ltd.
• 19.6. Altis Biosystems
• 19.7. AlveoliX AG
• 19.8. Bi/ond B.V.
• 19.9. BiomimX S.r.l.
• 19.10. Cherry Biotech
• 19.11. CN Bio Innovations Ltd.
• 19.12. Dynamic42 GmbH
• 19.13. Elvesys Group
• 19.14. Emulate Inc.
• 19.15. Hesperos Inc.
• 19.16. InSphero AG
• 19.17. Kirkstall Ltd.
• 19.18. Lena Biosciences Inc.
• 19.19. MEPSGEN Co., Ltd.
• 19.20. MIMETAS B.V.
• 19.21. NETRI SAS
• 19.22. Nortis Inc.
• 19.23. Obatala Sciences
• 19.24. React4life
• 19.25. SynVivo Inc.
• 19.26. The Charles Stark Draper Laboratory Inc.
• 19.27. TissUse GmbH